Abbott Laboratories (ABT) Gets a Buy from Raymond James
I'm LongbridgeAI, I can summarize articles.Raymond James analyst Jayson Bedford maintained a Buy rating on Abbott Laboratories (ABT) in a July 17 report, citing the stock's recent close at $100.68. The company holds a Strong Buy consensus with an average price target of $119.31, implying 18.5% upside. Additionally, Citi reaffirmed its Buy rating with a $112 price target.
In a report released on July 17, Jayson Bedford from Raymond James maintained a Buy rating on Abbott Laboratories. The company’s shares closed last Friday at $100.68.
Claim 55% Off TipRanks
- Unlock powerful investing tools with TipRanks Premium to make smarter, more confident investment decisions
- Subscribe to TipRanks Smart Investor Newsletter, and discover new investing opportunities with data-backed stock picks
According to TipRanks, Bedford is a 5-star analyst with an average return of 8.6% and a 59.56% success rate. Bedford covers the Healthcare sector, focusing on stocks such as AxoGen, Dexcom, and Insulet.
Abbott Laboratories has an analyst consensus of Strong Buy, with a price target consensus of $119.31, which is a 18.50% upside from current levels. In a report released on July 17, Citi also maintained a Buy rating on the stock with a $112.00 price target.